Interview: Konji Sebati – Chief Executive Officer, IPASA (Innovative…
The CEO of IPASA reveals how over the last ten months the priority has been to reach out to different stakeholders, rebuilding trust with the department of health, with patients…
In April 2013, South African research-based pharmaceutical companies that previously belonged to either Innovative Medicines SA (IMSA) or the Pharmaceutical Industry Association of South Africa (PIASA), integrated to form a new association: the Innovative Pharmaceutical Industry Association South Africa (IPASA). This move created a single, unified voice for like-minded pharmaceutical organisations operating in South Africa. IPASA represents 25 leading pharmaceutical companies who are dedicated to exploring, developing and bringing innovative, quality medicines to the South African market. Only companies that conduct their own research and development qualify for membership. As the South African representative of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), IPASA has global reach and access to the latest developments in medicines and treatments around the world. Working groups drawn from our member companies collaborate closely with an aim to contribute to the ongoing development of the South African healthcare sector.
Contact
PO Box 2945, Randburg, 2125
404 Main Avenue, cnr Oxford Road
Ferndale, Randburg, 2125
Tel: (011) 781 3256
Fax: (011) 781 3328
Web: ipasa.co.za/
E-mail: xolile@ipasa.co.za
The CEO of IPASA reveals how over the last ten months the priority has been to reach out to different stakeholders, rebuilding trust with the department of health, with patients…
The country president of Novartis South Africa reveals how Novartis has recently moved to new premises, demonstrating a clear commitment to continue investing in the country; why South Africa…
The managing director at Adcock Ingram Critical Care reveals the company’s unique business model. As a long-established division within Adcock Ingram, Critical Care operates with relative independence. What is the relationship…
The head of operations of Hetero South Africa talks about the need for a more efficient regulatory system with a fast track process for essential molecules, and how Hetero is…
The CEO of Ascendis Health talks about their business model, being a long-term investment company that brings together healthy businesses in the healthcare industry, and how the diversification of their product…
Merck’s managing director for South Africa and general manager for Southeast Africa reveals why the company takes a long-term perspective when investing in African countries, helping to shape healthcare systems,…
The general manager of Novagen Pharma reveals how they are the second largest supplier of ARVs within the private South African market, how there is much room for the generics…
The country manager and Global Established Products Business Lead at Pfizer South Africa reveals how the private sector is committed to expanding healthcare for South Africans, why her ambition is…
The country manager of Dr. Reddy´s South Africa explains that while the perception of the quality of generics has improved in South Africa, there is still a long way to…
The CEO of NAPM reveals how the main challenge facing his members is the length of time needed to register a generic product, taking up to four years and acting…
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Having spent two months as the head of Novartis South Africa, what is your first assignment as General Manager, could you share with our readers what were the surprises for…
Mr. Miller, you have been Vice President and Managing Director of Mylan’s operations in South Africa since 2008. What mission were you assigned back then, and in those three years,…
See our Cookie Privacy Policy Here
